IP Library Granted Patent US 12,195,747
Granted Patent B1
US 12,195,747 · App. 18/517,808 · Granted Jan 14, 2025

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/86C12N15/111C12N2310/141C12N2750/14141
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,747
App. No.
18/517,808
Granted
Jan 14, 2025
Kind
B1
Abstract

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

Claims (8)

1. A composition that comprises a recombinant plasmid (RP) comprising SEQ ID NO: 1 that comprises a start region and an end region, the RP further comprising an insert sequence positioned between the start region and the end region, in which the insert sequence comprises 95-100% of SEQ ID NO: 5 and the insert sequence encodes for micro-interfering ribonucleic acid (miRNA) that binds to and causes degradation of messenger ribonucleic acid (mRNA) that encodes for a target biomolecule.

2. The composition of claim 1 , wherein the insert sequence of nucleotides is configured to be delivered to a target cell that has an over-expressed or mis-expressed biomolecule, and wherein the RP is encased in a protein coat, a lipid vesicle, or any combination thereof.

3. The composition of claim 1 , wherein the insert sequence of nucleotides is configured to be delivered to a target cell that has an over-expressed or mis-expressed biomolecule, and wherein the RP is encased in a viral vector.

4. The composition of claim 3 , wherein the viral vector is a double stranded DNA virus, a single stranded DNA virus, a single stranded RNA virus, or a double stranded RNA virus.

5. The composition of claim 3 , wherein the viral vector is an adeno-associated virus.

6. The composition of claim 1 , wherein the target molecule is IL-17A.

7. A composition that comprises a recombinant plasmid (RP) comprising a sequence with 95-100% of SEQ ID NO: 15 that encodes for micro-interfering ribonucleic acid (miRNA) that binds to and causes degradation of messenger ribonucleic acid (mRNA) that encodes for a cytokine.

8. The composition of claim 7 , wherein the cytokine is IL-17A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072083/0016 →
References Cited (6)
CN 108998451A · 2018 [cited by examiner]
O'Brien et al., “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation,” Frontiers in Endocrinology, vol. 9, Article 402: 1-12 (Year: 2018). [cited by examiner]
Zhang et al., “The Risks of miRNA Therapeutics: In a Drug Target Perspective,” Drug Design, Development and Therapy 15: 721-733 (Year: 2021). [cited by examiner]
Zhang et al., “Cytokines, Inflammation and Pain”, Int. Anesthesiol. Clin. 54(2): 27-37 (Year: 2007). [cited by examiner]
WIPO translation of CN108998451A (Year: 2018). [cited by examiner]
Asirvatham et al., “miRNA regulation of cytokine genes”, Cytokine 45(2): 58-69 (Year: 2009). [cited by examiner]
Cited By (28)
US 12,497,619 US 12,497,620 US 12,509,686 US 12,509,692 US 12,509,693 US 12,516,324 US 12,516,327 US 12,516,328 US 12,522,828 US 12,522,829 US 12,522,831 US 12,522,832 US 12,522,833 US 12,534,733 US 12,540,322 US 12,540,328 US 12,540,329 US 12,553,051 US 12,553,052 US 12,559,751 US 12,559,752 US 12,559,756 US 12,565,652 US 12,565,655 US 12,565,657 US 12,595,484 US 12,644,124 US 12,680,103